Land: Malta
Språk: engelsk
Kilde: Medicines Authority
remifentanil 5 mg
Glaxo SmithKline UK Limited
N01AH06
remifentanil
powder for solution for injection
Authorised
2007-06-19
GSK LOGO PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ULTIVA FOR INJECTION REMIFENTANIL HYDROCHLORIDE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START HAVING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist (see section 4). WHAT IS IN THIS LEAFLET: 1 What Ultiva is and what it is used for 2 What you need to know before you are given Ultiva 3 How to have Ultiva 4 Possible side effects 5 How to store Ultiva 6 Contents of the pack and other information 1 WHAT ULTIVA IS AND WHAT IT IS USED FOR Ultiva contains a medicine called remifentanil. This belongs to a group of medicines known as opioids. Ultiva is used together with other medicines called anaesthetics • to help put you to sleep BEFORE an operation • to keep you asleep and stop you feeling pain DURING an operation • to make you feel sleepy and stop you feeling pain while you receive treatment in an Intensive Care Unit. 2 WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ULTIVA DO NOT HAVE ULTIVA IF: • you are allergic (hypersensitive) to remifentanil or any of the other ingredients of Ultiva (see section 6) • you are allergic (hypersensitive) to any other opioid medicines, such as morphine, codeine, alfentanil or fentanyl. If you are not sure if any of the above apply to you, talk to your doctor, nurse or pharmacist before having Ultiva. WARNINGS AND PRECAUTIONS Check with your doctor or pharmacist before having Ultiva if: • you are ove read_full_document
SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT Ultiva (remifentanil hydrochloride) for Injection 1 mg Ultiva (remifentanil hydrochloride) for Injection 2 mg Ultiva (remifentanil hydrochloride) for Injection 5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ultiva is a sterile, endotoxin-free, preservative-free, white to off white, lyophilized powder, to be reconstituted before use. When reconstituted as directed, solutions of Ultiva are clear and colourless and contain 1mg/ml of remifentanil base as remifentanil hydrochloride. Ultiva for injection is available in glass vials containing 1 mg, 2 mg or 5 mg of remifentanil base. 3. PHARMACEUTICAL FORM Lyophilized powder for reconstitution for intravenous administration. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision. Ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ULTIVA SHOULD BE ADMINISTERED ONLY IN A SETTING FULLY EQUIPPED FOR THE MONITORING AND SUPPORT OF RESPIRATORY AND CARDIOVASCULAR FUNCTION AND BY PERSONS SPECIFICALLY TRAINED IN THE USE OF ANAESTHETIC DRUGS AND THE RECOGNITION AND MANAGEMENT OF THE EXPECTED ADVERSE EFFECTS OF POTENT OPIOIDS, INCLUDING RESPIRATORY AND CARDIAC RESUSCITATION. SUCH TRAINING MUST INCLUDE THE ESTABLISHMENT AND MAINTENANCE OF A PATENT AIRWAY AND ASSISTED VENTILATION. Continuous infusions of Ultiva must be administered by a calibrated infusion device into a fast flowing IV line or via a dedicated IV line. This infusion line Page 1 of 28 read_full_document